documents are available for viewing by appointment for the duration of the Committee's term, which terminates after delivery of its final report to the Secretaries. Please call (202) 690–7102 to schedule an appointment to view the documents.

Dated: July 9, 2004.

### Penelope S. Royall,

Deputy Assistant Secretary for Health (Disease Prevention and Health Promotion), Department of Health and Human Services.

Dated: July 9, 2004.

### Eric J. Hentges,

Executive Director, Center for Nutrition Policy and Promotion, Department of Agriculture.

Dated: July 9, 2004

### Caird E. Rexroad Jr.,

Acting Associate Administrator, Agricultural Research Service, Department of Agriculture. [FR Doc. 04–16131 Filed 7–15–04; 8:45 am]
BILLING CODE 4150–32–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Program Announcement 04275]

Expansion of HIV/AIDS, STD and TB Laboratory Activities at the Namibia Institute of Pathology (NIP) in the Republic of Namibia; Notice of Intent To Fund Single Eligibility Award

### A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2004 funds for a cooperative agreement program to improve national surveillance for HIV infection, sexually transmitted diseases (STDs), and Tuburculosis (TB); and the capacity of the Namibia Institute of Pathology (NIP) to provide services for diagnosing these diseases and others related to HIV infection and transmission in Namibia. The Catalog of Federal Domestic Assistance number for this program is 93.941.

### **B.** Eligible Applicant

Assistance will be provided only to the Namibia Institute of Pathology.

The NIP is the only organization in Namibia qualified to collaborate with the Global AIDS Program (GAP) of CDC-Namibia because it has the legal authority, expertise and capacity to perform the key public health role of monitoring communicable diseases, such as AIDS, STD and TB. NIP has been charged by the Ministry of Health and Social Services (MOHSS) to serve as the national reference laboratory for

HIV, STD and TB, and to develop, implement and evaluate laboratory diagnostic and quality assurance activities related to these diseases. NIP has mechanisms in place to access information for, and the scientific expertise to apply these factors to, the development of laboratory capacity at the national and regional levels that will assist the government in its HIV, STD, and TB prevention programs. The major purpose of this announcement is to build upon the existing public health laboratory framework in Namibia. No other institution in the country has the capacity, legal mandate and expertise to accomplish this task.

### C. Funding

Approximately \$1,200,000 is available in FY 2004 to fund this award. It is expected that the award will begin on or before September 1, 2004 and will be made for a 12-month budget period within a project period of up to five years. Funding estimates may change.

### D. Where To Obtain Additional Information

For general comments or questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone: (770) 488–2700.

For technical questions about this program, contact: Dr. Tom Kenyon, Project Officer, Global AIDS Program (GAP), c/o U.S. Embassy Windhoek, 2540 Windhoek Place, Washington, DC 20521, Telephone: 264 61 203 2271, Fax number: 264 61 226 959, E-mail: TKenyon@cdc.gov.

Dated: July 12, 2004.

### William P. Nichols,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 04–16169 Filed 7–15–04; 8:45 am] BILLING CODE 4163–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

[Program Announcement 04106]

### Development of Influenza Surveillance Networks Amendment

A notice announcing the availability of fiscal year (FY2004 funds for a cooperative agreement entitled, "Development of Influenza Surveillance Networks" was published in the **Federal Register** Tuesday, April 27, 2004, Volume 69, Number 81, pages 22806–22810. The notice is amended as follows:

On page 22806, column one, after "Application Deadline": Please change the application deadline from June 28, 2004 to July 13, 2004. Also, on page 22808, column three, under section "IV.3. Submission Dates and Times", after "Application Deadline Date", please change the application deadline date from June 28, 2004 to July 13, 2004.

Dated: July 8, 2004.

#### Alan A. Kotch,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 04–16170 Filed 7–15–04; 8:45 am] **BILLING CODE 4163–18–P** 

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Study Effect of West Nile Virus Infections on Outcomes of Pregnancy in Humans, Program Announcement 04213

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Study Effect of West Nile Virus Infections on Outcomes of Pregnancy in Humans, Program Announcement 04213.

Times and Dates: 10:30 a.m.—11:10 a.m., August 10, 2004 (Open); 11:30 a.m.—2:30 p.m., August 10, 2004 (Closed).

Place: Teleconference number (404) 498–4115.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to: Study Effect of West Nile Virus Infections on Outcomes of Pregnancy in Humans, Program Announcement 04213.

Contact Person for More Information: Esther Sumartojo, PhD, MSc, Acting Associate Director for Science and Public Health, National Center on Birth Defects and Developmental Disabilities, CDC, 1600 Clifton Road, Mailstop E–87, Atlanta, GA 30333, telephone 404–498–3072.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices